scholarly journals Ovarian Hyperstimulation Syndrome as an Etiology of Obstructive Uropathy

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Creticus P. Marak ◽  
Amit Chopra ◽  
Narendrakumar Alappan ◽  
Ana M. Ponea ◽  
Achuta K. Guddati
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Ovarian Hyperstimulation Syndrome ◽  
Assisted Reproductive Technologies ◽  
Obstructive Uropathy ◽  
Controlled Ovarian Hyperstimulation ◽  
Reproductive Technologies ◽  
Ovarian Hyperstimulation ◽  
Volume Depletion ◽  
Intravascular Volume Depletion

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of controlled ovarian hyperstimulation (COH) protocols performed in women undergoing assisted reproductive technologies. Overstimulation of the ovaries results in the overproduction of vasoactive cytokines and mediators by the ovaries, thereby causing a generalized capillary leak and acute shift of protein-rich fluid from the intravascular compartment into the third space. This may lead to the development of ascites, pleural effusions, pericardial effusion, anasarca, intravascular volume depletion, hemoconcentration, oliguria, hypoalbuminemia and hypoproteinemia, electrolyte imbalances, acute renal failure, abdominal compartment syndrome, thromboembolic events, and adult respiratory distress syndrome. The only effective treatment available is prevention of the syndrome from developing by individualizing the stimulation protocol, especially in high-risk patients. Once the syndrome develops, the management is mainly supportive. Oliguria and some degree of acute renal failure commonly develop in patients with moderate to severe OHSS and are usually due to prerenal causes. Acute renal failure (ARF) secondary to obstructive uropathy is rare. Here we report a case of severe, life-threatening OHSS resulting in ARF secondary to obstructive uropathy.

scholarly journals Follitropin Delta as a State-of-the-Art Incorporated Companion for Assisted Reproductive Procedures: A Two Year Observational Study

Medicina ◽  
2021 ◽  
Vol 57 (4) ◽  
pp. 379
Author(s):  
Bogdan Doroftei ◽  
Ovidiu-Dumitru Ilie ◽  
Ana-Maria Dabuleanu ◽  
Roxana Diaconu ◽  
Radu Maftei ◽  
...  
Keyword(s):  
Observational Study ◽  
Ovarian Hyperstimulation Syndrome ◽  
Twin Pregnancy ◽  
Assisted Reproductive Technologies ◽  
State Of The Art ◽  
Follicle Stimulating Hormone ◽  
Exact Result ◽  
Reproductive Technologies ◽  
The Other ◽  
Ovarian Hyperstimulation

Background and objectives: The latest reports suggest that follitropin delta is a highly efficient recombinant human follicle-stimulating hormone (r-hFSH) that became a part of the current assisted reproductive technologies (ARTs). Therefore, the present study aims to assess a series of parameters (follicles, oocytes, and embryos) and further by the outcomes in women following the administration of follitropin delta. Materials and methods: This observational study included 205 women. They were aged between 21 and 43 years (mean 33.45) and an anti-Müllerian hormone (AMH) level ranging from 0.11 to 16.00 ng/dL (mean 2.89). Results: In accordance with the established methodology and following the centralization of data, a total of fifty-eight pregnancies (28.29%) were achieved; forty-five (36.88%) were achieved in women under 35 years and thirteen (15.66%) in women above 35 years. These figures are positively correlated with women’s age considering that the number of follicles >18 mm, oocytes fertilized and embryo(s) varies among groups. Regarding the interest parameters, we noted n = 1719 follicles > 18 mm, n = 1279 retrieved oocytes, and n = 677 embryos at day 3. On the other hand, the following figures have been registered in women above 35 years: 814–follicles > 18 mm, 612 oocytes retrieved and 301 embryos at day 3. During this study, we registered only three cases of abortions (n = 1–0.81% in women under 35 years and n = 2–2.40% in women above 35 years). Nine pregnancies (7.37%) were stopped from evolution in females under 35 years, and twelve pregnancies (n = 8–6.55% in women under 35 years, while n = 4 in women above 35 years) were unsuccessful. A twin pregnancy has been confirmed (1.20%) in women above 35 years, six ongoing pregnancies (4.91%) in those under 35 years, and two in both groups (one per group–n = 1–0.81%, and 1.20%–n = 1) in which we did not know the exact result were registered at the end of the established studied interval. However, there were also situations in which the treatment cause an over-reactivity or had no effect; n = 2 were non-responders, and n = 1 exhibited moderate ovarian hyperstimulation syndrome (OHSS). Conclusions: Based on our results, we strongly encourage the use of this recombinant gonadotropin on a much larger scale.

scholarly journals A Early Development of Severe Ovarian Hyperstimulation Syndrome following Ovulation Induction

JMS SKIMS ◽  
2011 ◽  
Vol 14 (1) ◽  
pp. 30-32
Author(s):  
Fayaz A Sofi ◽  
Wasim Ahmed ◽  
Ghulam Nabi Dhobi ◽  
Showkat Ali Mufti ◽  
Rafi Ahmed Jan ◽  
...  
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Ovulation Induction ◽  
Ovarian Hyperstimulation Syndrome ◽  
Capillary Permeability ◽  
Ovarian Hyperstimulation ◽  
Fatal Complication ◽  
Vitro Fertilization ◽  
Severe Ovarian Hyperstimulation Syndrome

Ovarian Hyperstimulation is a rare but potentially fatal complication of ovarian stimulation during treatment of infertility. Worldwide the incidence of this syndrome is increasing due to liberal use of invitro fertilization for management of infertility. The syndrome is characterized by cystic ovarian enlargement and abnormal capillary permeability due to secretion of vasogenic substances by ovaries. The syndrome is classified into early and late variants with early variants usually mild to moderate in severity. We present a case of severe ovarian hyperstimulation syndrome (OHSS) developing early in a 25-year female while undergoing In-vitro fertilization (IVF). Six days after ovulation induction, the woman developed ascites, bilateral pleural effusion and acute renal failure with ultrasound abdomen revealing bilateral cystic enlargement of ovaries. JMS 2011;14(1):30-32

Obstructive uropathy as the etiology of renal failure in ovarian hyperstimulation syndrome

2008 ◽  
Vol 89 (4) ◽  
pp. 992.e1-992.e2 ◽  
Author(s):  
David Alastair Merrilees ◽  
Andrew Kennedy-Smith ◽  
Richard G. Robinson
Keyword(s):  
Renal Failure ◽  
Ovarian Hyperstimulation Syndrome ◽  
Obstructive Uropathy ◽  
Ovarian Hyperstimulation

Efficacy of Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome: A Randomized, Double-blind and Placebo-controlled Trial

2017 ◽  
Vol 8 (2) ◽  
pp. 54-60
Author(s):  
Swati Singh ◽  
Sankalp Singh ◽  
Ambujakshy K Raman ◽  
Sujatha Ramakrishnan ◽  
C Mohamed Ashraf
Keyword(s):  
High Risk ◽  
Ovarian Hyperstimulation Syndrome ◽  
Assisted Reproductive Technologies ◽  
Controlled Trial ◽  
Fluid Collection ◽  
Reproductive Technologies ◽  
Total Leukocyte Count ◽  
Ovarian Hyperstimulation ◽  
Double Blind ◽  
Significant Difference

ABSTRACT Introduction Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication that arises due to assisted reproductive technologies (ARTs) during infertility treatment. Recently, the use of selective dopamine receptor agonists on D2 receptors (e.g., cabergoline) has been suggested in the prevention of OHSS. The aim of this study was to evaluate the effect of cabergoline in the prevention of OHSS in high-risk patients undergoing ART. Materials and methods This was a randomized, double-blind, parallel group (cabergoline group and placebo) study. A total of 110 women undergoing in vitro fertilization (IVF)–intracytoplasmic sperm injection procedure using a long agonist protocol with high risk for OHSS were recruited for the study on the day of final trigger. All the patients were followed up every 48 hours for 10 days from the day of the final trigger and clinically assessed with ultrasound and blood tests. The size of ovaries and fluid collection in the pouch of Douglas (POD) was measured with ultrasound. A sample size of 92 subjects was calculated for the study to be powered at 80%. Assuming a drop-out rate of 10%, 110 subjects were enrolled for the study. Results There was no significant difference observed in the size of right and left ovary, POD fluid volume, total leukocyte count (TLC), and serum estradiol level (E2 level) between both the groups from day 0 to day 8, except packed cell volume. No significant difference was observed in the incidence rate of moderate OHSS between both groups (p = 0.728). The differences in clinical pregnancy rate, implantation rate, and live birth rate were also insignificant. Conclusion Cabergoline does not reduce the incidence of moderate OHSS when compared with placebo. Large, well-designed studies are needed to evaluate the effectiveness of cabergoline when used for the prevention of OHSS. How to cite this article Singh S, Singh S, Raman AK, Ramakrishnan S, Ashraf CM. Efficacy of Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome: A Randomized, Double-blind and Placebo-controlled Trial. Int J Infertil Fetal Med 2017;8(2):54-60

scholarly journals Ovarian hyperstimulation syndrome after assisted reproductive technologies: trends, predictors, and pregnancy outcomes

2020 ◽  
Vol 114 (3) ◽  
pp. 567-578
Author(s):  
David A. Schirmer ◽  
Aniket D. Kulkarni ◽  
Yujia Zhang ◽  
Jennifer F. Kawwass ◽  
Sheree L. Boulet ◽  
...  
Keyword(s):  
Pregnancy Outcomes ◽  
Ovarian Hyperstimulation Syndrome ◽  
Assisted Reproductive Technologies ◽  
Reproductive Technologies ◽  
Ovarian Hyperstimulation

scholarly journals Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others?

2002 ◽  
Vol 17 (6) ◽  
pp. 1548-1553 ◽  
Author(s):  
Bernie McElhinney ◽  
Joy Ardill ◽  
Carolyn Caldwell ◽  
Freddie Lloyd ◽  
Neil McClure
Keyword(s):  
Ovarian Hyperstimulation Syndrome ◽  
Assisted Reproductive Technologies ◽  
Reproductive Technologies ◽  
Ovarian Hyperstimulation
Sign in / Sign up

Export Citation Format

Share Document